Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation

Neuropharmacology

Volumn 60, Issue 6, 2011, Pages 963-974

  Chung, Young C ^a   Kim, Sang R ^b,e   Park, Ju Young ^b   Chung, Eun S ^a   Park, Keun W ^a   Won, So Y ^a   Bok, Eugene ^a,b,c   Jin, Minyoung ^a   Park, Eun S ^a   Yoon, Sung Hwa ^b   Ko, Hyuk W ^a   Kim, Yoon Seong ^d   Jin, Byung K ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Ajou University   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

Fluoxetine; Microglial activation; Neuroinflammation; Oxidative stress; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; FLUOXETINE; INDUCIBLE NITRIC OXIDE SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL ACTIVATION; CELL LOSS; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENRICHMENT CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MICROGLIA; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; TRANSIENT EXPRESSION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL COUNT; COCULTURE TECHNIQUES; CORPUS STRIATUM; CYTOKINES; DOPAMINE; FLUOXETINE; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; MPTP POISONING; NADPH OXIDASE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; RECOVERY OF FUNCTION; ROTAROD PERFORMANCE TEST; SUBSTANTIA NIGRA;

EID: 79952449932     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.01.043     Document Type: Article

References (61)

1. Z.I. Alam, S.E. Daniel, A.J. Lees, D.C. Marsden, P. Jenner, and B. Halliwell A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease J. Neurochem. 69 1997 1326 1329 (Pubitemid 27364859)
2. M.S. Ansorge, E. Morelli, and J.A. Gingrich Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice J. Neurosci. 28 2008 199 207
3. K. Aquilano, S. Baldelli, G. Rotilio, and M.R. Ciriolo Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols Neurochem. Res. 33 2008 2416 2426
4. M.F. Beal Oxidatively modified proteins in aging and disease Free Radic. Biol. Med. 32 2002 797 803 (Pubitemid 34439250)
5. M.L. Block, and J.S. Hong Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog. Neurobiol. 76 2005 77 98 (Pubitemid 41242883)
6. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat. Rev. Neurosci. 8 2007 57 69 (Pubitemid 46011999)
7. L.M. Bolin, I. Strycharska-Orczyk, R. Murray, J.W. Langston, and D. Di Monte Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice J. Neurochem. 83 2002 167 175
8. J. Bove, D. Prou, C. Perier, and S. Przedborski Toxin-induced models of Parkinson's disease NeuroRx 2 2005 484 494 (Pubitemid 41444882)
9. + J. Neural Transm. 76 1989 1 12 (Pubitemid 19079357)
10. D.K. Choi, S. Pennathur, C. Perier, K. Tieu, P. Teismann, D.C. Wu, V. Jackson-Lewis, M. Vila, J.P. Vonsattel, J.W. Heinecke, and S. Przedborski Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice J. Neurosci. 25 2005 6594 6600 (Pubitemid 40995291)
11. S.H. Choi, D.Y. Lee, E.S. Chung, Y.B. Hong, S.U. Kim, and B.K. Jin Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo J. Neurochem. 95 2005 1755 1765 (Pubitemid 41804071)
12. S.H. Choi, D.Y. Lee, S.U. Kim, and B.K. Jin Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase J. Neurosci. 25 2005 4082 4090
13. Y.C. Chung, S.R. Kim, and B.K. Jin Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease J. Immunol. 185 2010 1230 1237
14. E. Croisier, L.B. Moran, D.T. Dexter, R.K. Pearce, and M.B. Graeber Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition J. Neuroinflammation 2 2005 14
15. A.R. Cross, and A.W. Segal The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems Biochim. Biophys. Acta 1657 2004 1 22 (Pubitemid 38823040)
16. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909 (Pubitemid 37130207)
17. T.M. Dawson, and V.L. Dawson Molecular pathways of neurodegeneration in Parkinson's disease Science 302 2003 819 822 (Pubitemid 37339614)
18. G. Dell'Agnello, R. Ceravolo, A. Nuti, G. Bellini, A. Piccinni, C. D'Avino, L. Dell'Osso, and U. Bonuccelli SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study Clin. Neuropharmacol. 24 2001 221 227 (Pubitemid 32717856)
19. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner, and C.D. Marsden Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J. Neurochem. 52 1989 381 389 (Pubitemid 19037600)
20. S. Fahn, and G. Cohen The oxidant stress hypothesis in Parkinson's disease: evidence supporting it Ann. Neurol. 32 1992 804 812
21. B. Ferger, A. Leng, A. Mura, B. Hengerer, and J. Feldon Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum J. Neurochem. 89 2004 822 833 (Pubitemid 38684730)
22. E. Floor, and M.G. Wetzel Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay J. Neurochem. 70 1998 268 275 (Pubitemid 28020852)
23. H.M. Gao, B. Liu, W. Zhang, and J.S. Hong Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease FASEB J. 17 2003 1954 1956
24. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski, and V.M. Lee Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions Science 290 2000 985 989
25. A. Giovanni, B.A. Sieber, R.E. Heikkila, and P.K. Sonsalla Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration to several strains of mice J. Pharmacol. Exp. Ther. 257 1991 691 697
26. A. Hald, and J. Lotharius Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol. 193 2005 279 290 (Pubitemid 40616179)
27. B. Han, and H. Zhao Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice Neurochem. Res. 35 2010 107 113
28. M.T. Heneka, H. Wiesinger, L. Dumitrescu-Ozimek, P. Riederer, D.L. Feinstein, and T. Klockgether Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease J. Neuropathol. Exp. Neurol. 60 2001 906 916 (Pubitemid 32880598)
29. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
30. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, and E.C. Hirsch Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 72 1996 355 363 (Pubitemid 26111202)
31. V. Jackson-Lewis, and S. Przedborski Protocol for the MPTP mouse model of Parkinson's disease Nat. Protoc. 2 2007 141 151 (Pubitemid 47044700)
32. Y. Jin, C.M. Lim, S.W. Kim, J.Y. Park, J.S. Seo, P.L. Han, S.H. Yoon, and J.K. Lee Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus Brain Res. 1281 2009 108 116
33. R. Kavya, R. Saluja, S. Singh, and M. Dikshit Nitric oxide synthase regulation and diversity: implications in Parkinson's disease Nitric Oxide 15 2006 280 294 (Pubitemid 44647899)
34. A. Kikuchi, A. Takeda, H. Onodera, T. Kimpara, K. Hisanaga, N. Sato, A. Nunomura, R.J. Castellani, G. Perry, M.A. Smith, and Y. Itoyama Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy Neurobiol. Dis. 9 2002 244 248 (Pubitemid 34261218)
35. S.R. Kim, D.Y. Lee, E.S. Chung, U.T. Oh, S.U. Kim, and B.K. Jin Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro J. Neurosci. 25 2005 662 671
36. S.U. Kim, and J. de Vellis Microglia in health and disease J. Neurosci. Res. 81 2005 302 313 (Pubitemid 41359284)
37. S.Y. Kim, K.C. Choi, M.S. Chang, M.H. Kim, Y.S. Na, J.E. Lee, B.K. Jin, B.H. Lee, and J.H. Baik The dopamine D2 receptor regulates the development of dopaminergic neurons via extracellular signal-regulated kinase and Nurr1 activation J. Neurosci. 26 2006 4567 4576
38. W.G. Kim, R.P. Mohney, B. Wilson, G.H. Jeohn, B. Liu, and J.S. Hong Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia J. Neurosci. 20 2000 6309 6316 (Pubitemid 30658427)
39. Y.S. Kim, D.H. Choi, M.L. Block, S. Lorenzl, L. Yang, Y.J. Kim, S. Sugama, B.P. Cho, O. Hwang, S.E. Browne, S.Y. Kim, J.S. Hong, M.F. Beal, and T.H. Joh A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation FASEB J. 21 2007 179 187 (Pubitemid 46052555)
40. P. Klevenyi, O. Andreassen, R.J. Ferrante, J.R. Schleicher Jr., R.M. Friedlander, and M.F. Beal Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity Neuroreport 10 1999 635 638 (Pubitemid 29333296)
41. L.P. Liang, J. Huang, R. Fulton, B.J. Day, and M. Patel An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity in vivo J. Neurosci. 27 2007 4326 4333 (Pubitemid 46640723)
42. G.T. Liberatore, V. Jackson-Lewis, S. Vukosavic, A.S. Mandir, M. Vila, W.G. McAuliffe, V.L. Dawson, T.M. Dawson, and S. Przedborski Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nat. Med. 5 1999 1403 1409
43. C.M. Lim, S.W. Kim, J.Y. Park, C. Kim, S.H. Yoon, and J.K. Lee Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect J. Neurosci. Res. 87 2009 1037 1045
44. R.L. Miller, M. James-Kracke, G.Y. Sun, and A.Y. Sun Oxidative and inflammatory pathways in Parkinson's disease Neurochem. Res. 34 2009 55 65
45. J.L. Montastruc, N. Fabre, O. Blin, J.M. Senard, O. Rascol, and A. Rascol Does fluoxetine aggravate Parkinson's disease? A pilot prospective study Mov. Disord. 10 1995 355 357
46. M. Moon, H.G. Kim, L. Hwang, J.H. Seo, S. Kim, S. Hwang, D. Lee, H. Chung, M.S. Oh, K.T. Lee, and S. Park Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation Neurotox. Res. 15 2009 332 347
47. T. Nagatsu, M. Mogi, H. Ichinose, and A. Togari Cytokines in Parkinson's disease J. Neural Transm. Suppl. 2000 143 151
48. M. Norcross, P. Mathur, A.J. Enoch, R.M. Karlsson, J.L. Brigman, H.A. Cameron, J. Harvey-White, and A. Holmes Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice Psychopharmacology (Berl) 200 2008 413 424
49. A. Oyagi, Y. Oida, H. Hara, H. Izuta, M. Shimazawa, N. Matsunaga, and T. Adachi Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease Brain Res. 1214 2008 169 176
50. K.W. Park, H.H. Baik, and B.K. Jin IL-13-induced oxidative stress via microglial NADPH oxidase contributes to death of hippocampal neurons in vivo J. Immunol. 183 2009 4666 4674
51. G. Paxinos, and K. Franklyn The Mouse Brain in Stereotaxic Coordinates 2001 Academic Press San Diego
52. S. Przedborski, V. Jackson-Lewis, R. Djaldetti, G. Liberatore, M. Vila, S. Vukosavic, and G. Almer The parkinsonian toxin MPTP: action and mechanism Restor. Neurol. Neurosci. 16 2000 135 142 (Pubitemid 30159159)
53. M.Y. Ryu, M.A. Lee, Y.H. Ahn, K.S. Kim, S.H. Yoon, E.Y. Snyder, K.G. Cho, and S.U. Kim Brain transplantation of neural stem cells cotransduced with tyrosine hydroxylase and GTP cyclohydrolase 1 in Parkinsonian rats Cell Transplant. 14 2005 193 202 (Pubitemid 40677149)
54. J.M. Savitt, V.L. Dawson, and T.M. Dawson Diagnosis and treatment of Parkinson disease: molecules to medicine J. Clin. Invest. 116 2006 1744 1754 (Pubitemid 44033293)
55. J.A. Simons Fluoxetine in Parkinson's disease Mov. Disord. 11 1996 581 582 (Pubitemid 26306088)
56. K. Sriram, J.M. Matheson, S.A. Benkovic, D.B. Miller, M.I. Luster, and J.P. O'Callaghan Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease FASEB J. 16 2002 1474 1476
57. P. Teismann, K. Tieu, O. Cohen, D.K. Choi, D.C. Wu, D. Marks, M. Vila, V. Jackson-Lewis, and S. Przedborski Pathogenic role of glial cells in Parkinson's disease Mov. Disord. 18 2003 121 129 (Pubitemid 36305454)
58. M.J. West, L. Slomianka, and H.J. Gundersen Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator Anat. Rec. 231 1991 482 497
59. D.C. Wu, P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, and S. Przedborski NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease Proc. Natl. Acad. Sci. U S A 100 2003 6145 6150 (Pubitemid 36576945)
60. J. Zhang, G. Perry, M.A. Smith, D. Robertson, S.J. Olson, D.G. Graham, and T.J. Montine Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons Am. J. Pathol. 154 1999 1423 1429 (Pubitemid 29226437)
61. C. Zhao, Z. Ling, M.B. Newman, A. Bhatia, and P.M. Carvey TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice Neurobiol. Dis. 26 2007 36 46 (Pubitemid 46437443)